Nasdaq GlobeNewswire

New England Journal of Medicine Publishes Novavax' NanoFlu Clinical Trial Data

Del
  • NanoFluTM Phase 1/2 trial data published in a peer-reviewed letter to the editor in The New England Journal of Medicine
  • NanoFlu demonstrates significantly improved immune responses against a panel of homologous and drifted A(H3N2) influenza viruses compared to leading licensed egg-based, high-dose flu vaccine in older adults
  • Phase 2 trial of quadrivalent NanoFlu expected to begin in third quarter of 2018

GAITHERSBURG, Md., June 13, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that The New England Journal of Medicine (NEJM) published a peer-reviewed letter to the editor detailing the positive results from Novavax' Phase 1/2 clinical trial in older adults comparing its Matrix- M(TM) adjuvanted nanoparticle seasonal influenza vaccine candidate (NanoFlu) to the leading licensed egg-based, high-dose influenza vaccine (IIV3-HD). The letter is available online at www.nejm.org/doi/full/10.1056/NEJMc1803554.

"We are pleased to be able to share the detailed data from the NanoFlu Phase 1/2 clinical trial with the broader scientific community," said Stanley C. Erck, President and Chief Executive Officer of Novavax, Inc. "The low effectiveness of seasonal influenza vaccines, and in particular the A(H3N2) component of the vaccine, during the 2017-2018 season emphasizes the need for a more effective vaccine. Our non-egg-based, recombinant nanoparticle vaccine, when coupled with Matrix-M, potentially offers broader protection against rapidly evolving drift strain variants. We believe this addresses important public health challenges caused by influenza and offers a significant advantage over current influenza vaccines."

In February 2018, Novavax reported the positive top-line results from the NanoFlu Phase 1/2 clinical trial in older adults. Details of the data, as published in this letter, include that NanoFlu in comparison to IIV3-HD induced:

  • Hemagglutination inhibition (HAI) immune responses that were 28 to 64% greater against the homologous and four generations of drifted wild-type A(H3N2) influenza strains; and
  • Higher HAI responses against the homologous A(H1N1) strain and comparable responses against the homologous B/Brisbane strain.

"These results showcase the potential benefit NanoFlu could have for older adults, a population challenged by poor immune responses. This population faces an urgent unmet medical need for a more effective flu vaccine, as highlighted by the severe flu season of 2017-2018," said Dr. Vivek Shinde, Executive Director, Clinical Development at Novavax and lead author of the letter. "We look forward to advancing this vaccine into the planned Phase 2 clinical trial of quadrivalent NanoFlu in the third quarter of 2018."

About the Phase 1/2 Clinical Trial

Novavax, Inc. conducted a randomized, observer-blind, comparator-controlled trial of NanoFlu (in two trivalent formulations: 45µg or 180µg total HA) against IIV3-HD in 330 healthy adults aged 60 years or older. Immunogenicity was measured by HAI and neutralization antibody responses against a panel of vaccine-homologous, and historically and forward-drifted, influenza virus strains.

About NanoFlu(TM) and Matrix M(TM)

NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are substantially the same as wild-type circulating virus HA sequences. NanoFlu contains Novavax' patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and NanoFlu vaccine candidates are Novavax' most advanced clinical programs and are at the forefront of its efforts to improve global health. For more information, please visit www.novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contact:

Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Nasdaq Launches ESG futures in the Nordics15.10.2018 10:00Pressemelding

STOCKHOLM, Sweden, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of futures based on the recently launched OMXS30 ESG Responsible index (OMXS30ESG). The product is the first exchange listed and ESG compliant index future in the world. “In recent years we have seen institutions increase efforts to integrate sustainability into their investment strategies, with the Nordic region being in the forefront of this trend,” says Alessandro Romani, Head of European Equity Derivatives at Nasdaq. “Those looking to invest in a more sustainable way need more investment products based on established and liquid indexes. Our existing OMXS30 index future contract is among the most traded in Europe and we expect to see the same interest for the ESG version.” The OMXS30ESG Index was developed in cooperation with a number of leading Nordic asset managers, including Swedbank Robur. “At Swedbank, innovation and constant development are an important part of the business, a

Telix and ANMI Expand PSMA Imaging Partnership15.10.2018 00:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has expanded its partnership with Advanced Nuclear Medicine Ingredients SA (“ANMI”) for the 68Ga-HBED-CC-PSMA-11 (68Ga-PSMA) cold kit. The 68Ga-PSMA kit is developed by ANMI and commercialized by Telix for the US market where it is marketed as illumetTM . In response to considerable clinical interest in the illumetTM product, Telix has commenced scale-up manufacturing in the United States, following the recent filing of a drug master file (DMF) and the launch of several major clinical trials using the product, including the 750 patient VISION phase III trial (Endocyte, Inc.) and a 500-patient phase II study at Memorial Sloan Kettering C

Brookfield Asset Management 2018 Third Quarter Results Conference Call And Webcast12.10.2018 15:33Pressemelding

Date: Thursday, November 8, 2018 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Third Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2018 Third Quarter Conference Call & Webcast on Thursday, November 8, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial (877) 255-3077 toll free in North America, or for overseas calls please dial (647) 252-4453 at approximately 10:50 a.m. The Conference Call will also be Webcast live at htt

Wasabi to Open its First European Data Center in Amsterdam11.10.2018 18:17Pressemelding

Provides Hot Cloud Storage Service for European Markets While Expanding Global Presence Boston, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Wasabi, the hot cloud storage company, today announces plans to open its first European data center in Amsterdam, NL this coming December. With the addition of its latest data center, Wasabi will make its international debut by offering EU markets the lowest cost, highest performance cloud storage service available, now with very low latency for European customers. Wasabi’s hot cloud storage service enables companies to store their data at one-fifth the cost and 6x the speed of Amazon S3 with no additional egress fees. Wasabi customers will have more connectivity options, additional data center redundancy, automatic data replication and failover services, and faster speeds with close proximity to their own data centers. With its newest data center opening, Wasabi enables high-speed exchange between Wasabi storage and customer compute resources with multiple

SIMEX reduces trading commissions11.10.2018 16:50Pressemelding

American Retail Group Inc. (aka Simex Inc.) the public corporation organized in the State of Nevada, USA LAS VEGAS, Oct. 11, 2018 (GLOBE NEWSWIRE) -- (OTC: ARGB) -- SIMEX Inc. announces reducing trading commissions. Current trading commissions are set to 0.1% for both sides maker/taker which is 50% lower than before. Vassili Oxenuk, the President of SIMEX, said: "By reducing trading commissions we become more attractive to traders on the digital assets market." Trading commissions can be even reduced to 0%. SMX Token allows you to reduce the commissions when trading on the SIMEX Exchange. Commissions rate depending on the balance of the user's account*: 1 000 SMX: 0.075% Maker / 0.075% Taker. 5 000 SMX: 0.05% Maker / 0.05% Taker. 10 000 SMX: 0% Maker / 0% Taker. Contact information: Email: info@simex.global Headquarters: 2300 West Sahara, Office 400, Las Vegas, 89102

Fortuna reports heavy seasonal rains caused an overflow in a contingency pond of the dry stack tailings facility at the San Jose Mine, Mexico11.10.2018 16:46Pressemelding

VANCOUVER, B.C., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that in the early morning of October 8th, abnormally high rainfall caused a contingency pond to overflow at the dry stack tailings facility at the San Jose mine located in Oaxaca, Mexico. The contingency pond collects water from a ditch system at the dry stack facility designed to capture and manage rain water. The Company wants to emphasize that no industrial process water was discharged in this incident and that the San Jose operation uses a cyanide-free process to produce concentrate. The dry stack contingency pond’s holding capacity is 7,000 cubic meters and it is equipped with a 600 cubic meter per hour pumping capacity that was surpassed by the volume of rain fall. The overflow occurred for about two hours at approximately 4:00 am and resulted in the spill of approximately 1,500 cubic meters of water carrying sediment and minor amounts of fine tailings from the facility’s d

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom